Page 2 - Cipla Ltd News

Cipla rallies 4%, hits 52-week high; Choice Broking sees more upside

Cipla stock outlook: A decisive breakout above ₹1,580 could trigger further upward momentum, paving the way towards the ₹1,770-₹1,850 target range in the medium term, said Choice Broking.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

847 of 3,147 stocks on NSE formed Bearish Marubozu pattern; what it means?

Apart from Nifty, 1 in every 4 stocks traded on NSE on Sept 4 recorded the day's high at open, and closed near the day's low; thus forming a 'Bearish Marubozu' candlestick pattern on the daily chart.

Tariffs, costs, and shifting strategies: Indian pharma's new playbook

Analysts say Indian pharma firms will increase focus on non-US exports and the domestic market as US tariff threats persist, with firms exploring offshore manufacturing options

Mixed Q1 results for top drug firms amid price erosion, tariff threat

Fresh launches boosted growth for players like Lupin, Torrent

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Cipla Q1 net profit up 10%, driven by consumer health and generics

Cipla reports a 10% increase in Q1FY26 net profit, fueled by strong performance in the generics and consumer health segments

Cipla Q1 FY26 result: Net profit jumps 10% at ₹1,298 cr, income rises 4%

The company said that its revenue fro the One-India business (operations within India) grew 6 per cent year-on-year, crossing ₹3,000 crore for the first time in any opening quarter of a financial year

Q1 results today: Cipla, SAIL, Bank of Baroda among 85 firms on July 25

Q1 FY26 company results, July 25: Bajaj Finserv, Shriram Finance, Reliance Infrastructure, Orient Cement, and ACME Solar will also release their April-June quarter earnings reports today

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore, expanding its presence in the respiratory diagnostics segment with a strategic investment in medical device development